Literature DB >> 10408859

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.

M N Holten-Andersen1, G Murphy, H J Nielsen, A N Pedersen, I J Christensen, G Høyer-Hansen, N Brünner, R W Stephens.   

Abstract

A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity, stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2+/-13.1 microg I(-1)) correlated with TIMP-1 measured in EDTA plasma (mean 73.5+/-14.2 microg I(-1)) from the same individuals in a set of 100 healthy blood donors (Spearman's rho = 0.62, P< 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes' stage D colorectal cancer was 240+/-145 microg I(-1) and a Mann-Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292+/-331 microg I(-1)). The results show that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer. It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408859      PMCID: PMC2362309          DOI: 10.1038/sj.bjc.6690384

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

Review 1.  The matrix-degrading metalloproteinases.

Authors:  L M Matrisian
Journal:  Bioessays       Date:  1992-07       Impact factor: 4.345

2.  Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma.

Authors:  D Moutsiakis; P Mancuso; H Krutzsch; W Stetler-Stevenson; S Zucker
Journal:  Connect Tissue Res       Date:  1992       Impact factor: 3.417

Review 3.  The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction.

Authors:  R Khokha; P Waterhouse
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

5.  Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2).

Authors:  D E Kleiner; A Tuuttila; K Tryggvason; W G Stetler-Stevenson
Journal:  Biochemistry       Date:  1993-02-16       Impact factor: 3.162

6.  A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies.

Authors:  N Fujimoto; J Zhang; K Iwata; T Shinya; Y Okada; T Hayakawa
Journal:  Clin Chim Acta       Date:  1993-10-29       Impact factor: 3.786

Review 7.  Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis.

Authors:  W G Stetler-Stevenson; L A Liotta; D E Kleiner
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

8.  Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells.

Authors:  R Khokha; M J Zimmer; C H Graham; P K Lala; P Waterhouse
Journal:  J Natl Cancer Inst       Date:  1992-07-01       Impact factor: 13.506

Review 9.  Tumor invasion, proteolysis, and angiogenesis.

Authors:  U P Thorgeirsson; C K Lindsay; D W Cottam; D E Gomez
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Serum metalloproteinases and their inhibitors: markers for malignant potential.

Authors:  T Baker; S Tickle; H Wasan; A Docherty; D Isenberg; J Waxman
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more
  31 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

Review 3.  Banking of biological fluids for studies of disease-associated protein biomarkers.

Authors:  Anne-Sofie Schrohl; Sidse Würtz; Elise Kohn; Rosamonde E Banks; Hans Jørgen Nielsen; Fred C G J Sweep; Nils Brünner
Journal:  Mol Cell Proteomics       Date:  2008-08-01       Impact factor: 5.911

4.  Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

Authors:  Bodil E Engelmann; Annika Loft; Andreas Kjær; Hans J Nielsen; Thomas A Gerds; Eric V Benzon; Nils Brünner; Ib J Christensen; Susanne H Hansson; Niels H Holländer; Michael H Kristensen; Johan Löfgren; Elena Markova; Carsten Sloth; Liselotte Højgaard
Journal:  Oncologist       Date:  2014-01-22

5.  Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material.

Authors:  Martin Lundberg; Stine Buch Thorsen; Erika Assarsson; Andrea Villablanca; Bonnie Tran; Nick Gee; Mick Knowles; Birgitte Sander Nielsen; Eduardo González Couto; Roberto Martin; Olle Nilsson; Christian Fermer; Jörg Schlingemann; Ib Jarle Christensen; Hans-Jorgen Nielsen; Björn Ekström; Claes Andersson; Mats Gustafsson; Nils Brunner; Jan Stenvang; Simon Fredriksson
Journal:  Mol Cell Proteomics       Date:  2011-01-17       Impact factor: 5.911

6.  Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery.

Authors:  Robert Cunningham; Di Ma; Lingjun Li
Journal:  Front Biol (Beijing)       Date:  2012-08-01

Review 7.  Biomarkers for colorectal cancer.

Authors:  Takuji Tanaka; Mayu Tanaka; Takahiro Tanaka; Rikako Ishigamori
Journal:  Int J Mol Sci       Date:  2010-09-13       Impact factor: 5.923

8.  Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue.

Authors:  P A Usher; A M Sieuwerts; A Bartels; U Lademann; H J Nielsen; L Holten-Andersen; J A Foekens; N Brünner; H Offenberg
Journal:  Mol Oncol       Date:  2007-05-21       Impact factor: 6.603

9.  TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.

Authors:  Xiaohong Deng; Louise Fogh; Ulrik Lademann; Vibeke Jensen; Jan Stenvang; Huanming Yang; Nils Brünner; Anne-Sofie Schrohl
Journal:  Tumour Biol       Date:  2013-01-22

10.  Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.

Authors:  Anne-Sofie Schrohl; Maxime P Look; Marion E Meijer-van Gelder; John A Foekens; Nils Brünner
Journal:  BMC Cancer       Date:  2009-09-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.